Nek­tar sues Lil­ly, claim­ing its in­ter­est in biotech’s au­toim­mune drug ‘waned dra­mat­i­cal­ly’ af­ter buy­ing Der­mi­ra

Nek­tar Ther­a­peu­tics is tak­ing Eli Lil­ly to court in Cal­i­for­nia, say­ing the In­di­anapo­lis-based drug­mak­er mis­han­dled da­ta and “ex­e­cut­ed on a scheme to en­sure that REZPEG …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER